Company Filing History:
Years Active: 2025
Title: Atharva Karulkar: Innovator in Immunotherapy
Introduction
Atharva Karulkar is a notable inventor based in Mumbai, India. He has made significant contributions to the field of immunotherapy through his innovative research and development efforts. His work focuses on advancing treatments for diseases associated with the expression of the Cluster of Differentiation 19 protein (CD19).
Latest Patents
Karulkar holds a patent for a "Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation." This invention relates to a novel humanized anti-CD19 chimeric antigen receptor that contains an optimized anti-CD19 binding domain. It is effective in treating diseases linked to CD19 expression. The patent also includes a nucleic acid molecule encoding the humanized CAR, a process for its preparation, and compositions containing the CAR. Additionally, it encompasses vectors containing the polynucleotide encoding the CAR and cells expressing the CAR on their surface, particularly for use in immunotherapy.
Career Highlights
Atharva Karulkar is affiliated with the Indian Institute of Technology Bombay, where he conducts his research. His work has garnered attention for its potential impact on therapeutic strategies in immunology.
Collaborations
Karulkar collaborates with esteemed colleagues, including Rahul Purwar and Alka Dwivedi, who contribute to his research endeavors.
Conclusion
Atharva Karulkar's innovative work in developing a humanized anti-CD19 chimeric antigen receptor represents a significant advancement in immunotherapy. His contributions are poised to enhance treatment options for patients suffering from diseases related to CD19 expression.